Moderna Inc. ($MRNA) Stock Forecast: Up 6.5% Today

What is Moderna Inc.?

A biotechnology company, Moderna (MRNA) stands out for its groundbreaking mRNA technology and dedication to developing vaccines and therapeutics. The company's stock has seen an upward trend, influenced by optimistic market sentiment and excitement around upcoming product launches.

Why is Moderna Inc. going up?

MRNA stock is up 6.5% on Jun 23, 2026 14:06

• Following a positive outcome from an FDA advisory committee vote on the benefit-risk profile of their seasonal flu vaccine, mRNA-1010, Moderna's stock witnessed a significant rise. This development has bolstered investor confidence in the company's vaccine portfolio.
• The market's response to Moderna's recent announcement contrasts with another company's stock decline, emphasizing the importance of regulatory approvals and product advancements in shaping stock performance.
• Moderna's stock upsurge mirrors investors' confidence in its growth potential, driven by its mRNA technology and upcoming product launches. It signifies a strong market belief in Moderna's capacity to provide innovative healthcare solutions.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

VeriSign Stock Slid Despite Strong Results, But Is The Real Test Still To Come?

VeriSign (VRSN) stock recently dropped about 20% despite strong earnings, hitting a record 176.1 million .com and .net domains and raising full-year guidance. This sell-off is attributed to market apprehension over a planned price increase for .com domains effective November 1, raising questions about potential impacts on growth. While history shows similar past dips in VRSN have been buying opportunities, the current valuation remains somewhat pricey, making the upcoming growth trend of domain name bases a key indicator for future performance.

https://www.trefis.com/stock/vrsn/articles/604038/verisign-stock-slid-despite-strong-results-but-is-the-real-test-still-to-come/2026-06-23

FDA Votes in Favor of Benefit-Risk Profile for Moderna’s Flu Vaccine

An FDA advisory committee has unanimously voted that the benefits of Moderna's seasonal flu vaccine, mRNA-1010, outweigh its risks for adults aged 50 and older. This decision is a part of the agency's ongoing review of Moderna's biologics license application for the potential new treatment. The FDA will consider these recommendations in its final decision.

https://www.wsj.com/health/pharma/fda-votes-in-favor-of-benefit-risk-profile-for-modernas-flu-vaccine-11821d88

Why BDC Income Investors Are Facing Smaller Quarterly Checks in 2026

Investors in Business Development Company (BDC) income funds like the Putnam BDC Income ETF (PBDC) are experiencing reduced quarterly distributions due to recent Federal Reserve rate cuts. These rate cuts have compressed income from floating-rate loans held by BDCs, leading to smaller payouts. PBDC recently cut its April 2026 distribution by 14% to $0.71, its lowest ever, primarily due to concentrated exposure to BDCs like Blue Owl that have weakening earnings coverage.

https://247wallst.com/investing/2026/06/22/why-bdc-income-investors-are-facing-smaller-quarterly-checks-in-2026/

Thermo Fisher Scientific Showcases New Capabilities Across Manufacturing, Clinical Development and AI-Enabled Research at BIO International 2026

Thermo Fisher Scientific is showcasing new capabilities and strategic investments at BIO International 2026, focusing on advanced manufacturing, clinical development, and AI-enabled research. These initiatives aim to accelerate innovation, simplify complex workflows, and expedite therapy delivery to patients. The company highlights its expanded manufacturing capacities, enhanced clinical research with data intelligence, and advancements in AI-enabled research through collaborations with key technology partners.

https://www.biospace.com/press-releases/thermo-fisher-scientific-showcases-new-capabilities-across-manufacturing-clinical-development-and-ai-enabled-research-at-bio-international-2026

Should You Buy Moderna Before Aug. 5?

Moderna's stock has surged over 100% this year, fueled by its mRNA technology and potential new product launches. Investors are anticipating a crucial FDA decision by August 5 regarding its investigational flu vaccine, mRNA-1010, which received a unanimous positive recommendation from an advisory panel. While the stock may see a short-term pop if approved, long-term growth investors might find better buying opportunities on dips after the initial announcement.

https://www.theglobeandmail.com/investing/markets/stocks/MRNA/pressreleases/2592125/should-you-buy-moderna-before-aug-5/

Trending Today

Wix.com Ltd. ($WIX) Stock Forecast: Down 5.9% Today

CDW Corporation ($CDW) Stock Forecast: Up 5.3% Today

Corning Incorporated ($GLW) Stock Forecast: Down 7.5% Today

International Business Machines Corporation ($IBM) Stock Forecast: Up 5.9% Today

C.H. Robinson Worldwide Inc. ($CHRW) Stock Forecast: Down 5.1% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 9.8% Today

Microchip Technology Incorporated ($MCHP) Stock Forecast: Down 8.5% Today

Analog Devices Inc. ($ADI) Stock Forecast: Down 8.4% Today

Xerox Corporation ($XRX) Stock Forecast: Up 5.1% Today

Carnival Corporation ($CCL) Stock Forecast: Down 5.1% Today

Moderna Inc. Price History

12.05.2026 - MRNA Stock was up 5.2%

• Moderna's stock rose nearly 8%, in line with Nasdaq's recovery and positive market sentiment.
• Investor interest is high in Moderna's mRNA cancer vaccine pipeline, particularly with the approval of a new trial for mRNA-4194 in Lynch syndrome patients by UK regulators.
• Analysts are recommending a "Hold" on Moderna despite the stock's rise, with an average target price lower than the current closing value.
• The upswing in Moderna's stock may also be linked to a legal conflict with BioNTech regarding patent infringement, with Moderna asserting that its new COVID-19 vaccine does not infringe upon BioNTech's intellectual property, adding an intriguing element to the stock's movement.

16.05.2026 - MRNA Stock was up 5.7%

• Moderna's strong bullish movement today can be attributed to the strategic organizational changes announced by the company, signaling preparations for multiple product launches in 2027 and 2028.
• The appointment of Ester Banque as Chief Commercial Officer and the expanded role of President Stephen Hoge to oversee key operations and product launches have instilled confidence in investors regarding the company's future growth prospects.
• Despite reported wider-than-expected quarterly losses and a consensus "Reduce" rating from analysts, the market seems to be focusing more on the long-term potential of Moderna's upcoming vaccine launches, leading to the positive stock movement.

17.05.2026 - MRNA Stock was up 6.1%

• This company held an Investor Event Science Day to showcase its research and development programs, particularly emphasizing innovation using mRNA technology, which likely boosted investor confidence.
• Collaboration with the FDA for an mRNA flu vaccine and positive developments in the biopharma industry, along with growing interest in biotech IPOs and ongoing industry challenges, contributed to the positive sentiment.
• Stock gains were also influenced by new product releases and advancements in the company's pipeline, strengthening its market position.
• The bullish movement observed today can be attributed to a combination of positive developments, technological advancements, and investor confidence in the biopharma industry.

16.05.2026 - MRNA Stock was up 11.4%

• Moderna's stock surge is linked to the favorable developments related to its mRNA-1010 seasonal flu vaccine. The FDA has shown support for the company's key immunogenicity data, despite some remaining uncertainties.
• Recent changes within Moderna's leadership team, such as the appointment of a new Chief Commercial Officer and expanded roles for key executives, indicate the company's strategic readiness for potential product launches. This has bolstered investor confidence in Moderna's future prospects.
• Verition Fund Management LLC has significantly increased its stake in Moderna, suggesting a growing investor interest in the company. Despite Moderna reporting a wider-than-expected quarterly loss, the positive outlook on the company's upcoming product launches appears to outweigh immediate financial concerns.

16.05.2026 - MRNA Stock was up 9.5%

• Moderna's stock saw a 9.5% surge due to favorable feedback from FDA staff regarding its flu vaccine candidate, mFlusiva, especially on its strong immune response in adults aged 65 and above. This positive development bolstered investor confidence in Moderna's vaccine projects.
• Initially met with some doubts from FDA scientists, the agreement between Moderna and the FDA on immunogenicity data pertaining to older adults before the upcoming advisory committee meeting on June 18th played a pivotal role in the stock's upward trajectory.
• The appointment of Ester Banque as Chief Commercial Officer and the expanded responsibilities of President Stephen Hoge indicate Moderna's strategic groundwork for potential product launches, such as flu and norovirus vaccines, supporting favorable market outlook towards the company.
• The regulatory process concerning Moderna's flu vaccine, with lingering uncertainties on its long-term safety and efficacy for specific demographics, will be a crucial determinant affecting the company's stock performance in the coming period.

17.05.2026 - MRNA Stock was up 10.8%

• Moderna's bullish movement today could be attributed to the anticipation and positive sentiment surrounding its upcoming Investor Event Science Day, where the company will showcase its research and development programs, emphasizing the potential of its mRNA platform in new therapeutic areas.
• The alignment with the FDA for its mRNA flu vaccine and the upcoming advisory committee meeting might have also contributed to investor optimism, reflecting confidence in Moderna's pipeline and regulatory progress.
• The broader industry trends, such as the surge in biotech IPOs and positive clinical results from other companies like Eli Lilly, could have created a favorable environment for Moderna's stock to thrive amidst growing interest in the biopharmaceutical sector.
• Overall, Moderna's strong performance today could be seen as a culmination of positive news flow, market dynamics, and investor expectations aligning in favor of the company's growth prospects.

17.05.2026 - MRNA Stock was up 6.3%

• Moderna's market uptick is linked to upbeat investor views following the Investor Event Science Day announcement. The event highlighted the company's research and development efforts, underscoring the potential of its mRNA platform in conjunction with AI and robotics.
• Collaboration with the FDA on its mRNA flu vaccine and the upcoming advisory committee meeting also played a role in the market's positive reaction, suggesting progress in Moderna's pipeline.
• The rise in biotech IPOs and ongoing biopharma sector developments may have contributed to the favorable climate for Moderna's stock, with investors expressing optimism about the industry's growth prospects.
• In general, Moderna's strategic actions, along with positive industry trends, likely drove today's bullish market performance.

18.05.2026 - MRNA Stock was up 5.5%

• Moderna's bullish movement today could be attributed to the company considering acquiring BioNTech's German manufacturing plants. This strategic move not only expands Moderna's production capacity but also positions it favorably in the European market.
• Additionally, the FDA clearance for Beam Therapeutics' BEAM-304 PKU gene-editing trial may have indirectly boosted Moderna's stock, as it highlights the advancements in genetic therapies within the biotech sector.
• The FDA scrutiny of Moderna's mRNA flu vaccine could have also impacted the stock positively, as it demonstrates the company's commitment to expanding its vaccine portfolio beyond COVID-19 solutions.
• Overall, Moderna's proactive approach towards acquisitions, clinical trials, and vaccine development seems to have resonated well with investors, driving the bullish movement in its stock price today.

18.05.2026 - MRNA Stock was up 8.0%

• Moderna's bullish movement can be attributed to the positive news surrounding its mRNA flu vaccine facing FDA scrutiny for approval in older adults. This potential approval would mark a significant milestone for the company, especially in the competitive flu vaccine market.
• The anticipation of Moderna entering the flu vaccine market with its mRNA technology, competing with traditional vaccine companies like Sanofi and GSK, has likely sparked investor optimism and contributed to the bullish trend.
• Investors may view Moderna's innovative approach to vaccine development and its potential expansion into new markets as a positive sign for the company's growth prospects, driving the stock price higher.
• The news of Moderna's mRNA flu vaccine progress overshadowed other headlines in the biotechnology sector, keeping the focus on the company's promising developments and future potential.

23.05.2026 - MRNA Stock was up 6.5%

• Following a positive outcome from an FDA advisory committee vote on the benefit-risk profile of their seasonal flu vaccine, mRNA-1010, Moderna's stock witnessed a significant rise. This development has bolstered investor confidence in the company's vaccine portfolio.
• The market's response to Moderna's recent announcement contrasts with another company's stock decline, emphasizing the importance of regulatory approvals and product advancements in shaping stock performance.
• Moderna's stock upsurge mirrors investors' confidence in its growth potential, driven by its mRNA technology and upcoming product launches. It signifies a strong market belief in Moderna's capacity to provide innovative healthcare solutions.

22.05.2026 - MRNA Stock was down 5.2%

• Confirmation of Moderna's mRNA flu vaccine, mRNA-1010, passing the FDA Advisory Committee meeting is viewed positively, notwithstanding concerns about weak operational performance and high valuation.
• Leerink Partners' adjustment of the price target and maintenance of an "Underperform" rating are seen as contributing to the prevailing negative sentiment.
• Despite a recent 6-day streak of gains and a significant increase in market capitalization, worries regarding the company's financial health and valuation being deemed "Very Unattractive" may have overshadowed any positive trend.
• The $2.25 billion settlement with Roivant Sciences could have adversely affected Moderna's stock, despite providing legal clarity, as investors might be wary of its implications on Moderna's finances and future prospects.

11.05.2026 - MRNA Stock was up 5.2%

• Recent investment by Nicollet Investment Management Inc. reflects strong confidence in Moderna's future, potentially influencing the stock price.
• The success of Parabilis Medicines' IPO and positive news about a new drug candidate may have positively impacted investor sentiment towards the biotech industry, which could benefit Moderna.
• Letko Brosseau & Associates Inc. selling some of their Moderna shares might indicate a strategic move to capitalize on past stock price gains.
• Comparisons between NVIDIA and GLOBALFOUNDRIES showcasing positive attitudes towards tech and biotech stocks could indirectly support Moderna's upward movement.